| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2024 | Aug 14, 2024 | Q32 Bio Inc. | Director | Sell | 47.5 | -265 | -3.21% | ✗ | $6.4K |
| Jan 1, 2024 | Feb 15, 2024 | Q32 Bio Inc. | Director | Sell | 33.8 | -13,037 | -9.19% | ✓ | $7.4K |
| Jan 9, 2023 | Jan 11, 2023 | Q32 Bio Inc. | Director | Sell | 32.5 | -10,616 | -8.92% | ✓ | $14.8K |
| Jan 1, 2022 | Jan 12, 2022 | Q32 Bio Inc. | CEO | Sell | 36.3 | -5,354 | -5.86% | ✓ | $20.2K |
| Feb 19, 2021 | Feb 23, 2021 | Stoke Therapeutics, Inc. | Director | Sell | 7.5 | -10,000 | -100.00% | ✓ | $606.7K |
| Nov 23, 2020 | Nov 25, 2020 | Stoke Therapeutics, Inc. | Director | Sell | 7.5 | -20,000 | -100.00% | ✓ | $920.6K |
| Feb 3, 2020 | Feb 5, 2020 | Q32 Bio Inc. | CEO | Sell | 25.0 | -12,500 | -13.89% | ✓ | $202K |
| Jan 2, 2020 | Jan 3, 2020 | Q32 Bio Inc. | CEO | Sell | 22.5 | -12,500 | -12.19% | ✓ | $256.2K |
| Nov 29, 2019 | Dec 3, 2019 | Q32 Bio Inc. | CEO | Sell | 17.5 | -25,000 | -19.61% | ✓ | $403.7K |
| Oct 1, 2019 | Oct 2, 2019 | Q32 Bio Inc. | CEO | Sell | 28.8 | -12,500 | -8.93% | ✓ | $217.5K |
| Sep 3, 2019 | Sep 5, 2019 | Q32 Bio Inc. | CEO | Sell | 28.8 | -12,500 | -8.20% | ✓ | $234.3K |
| Aug 1, 2019 | Aug 5, 2019 | Q32 Bio Inc. | CEO | Sell | 28.8 | -12,500 | -7.58% | ✓ | $217.1K |
| Jul 1, 2019 | Jul 3, 2019 | Q32 Bio Inc. | CEO | Sell | 32.5 | -12,500 | -7.04% | ✓ | $237.3K |
| Jun 3, 2019 | Jun 5, 2019 | Q32 Bio Inc. | CEO | Sell | 32.5 | -12,500 | -6.58% | ✓ | $248.3K |
| Apr 9, 2015 | Apr 9, 2015 | Tempest Therapeutics, Inc. | President | Buy | 90.0 | +225 | 19.15% | ✗ | $6.5K |
| Apr 8, 2015 | Apr 8, 2015 | Tempest Therapeutics, Inc. | President | Buy | 90.0 | +175 | 17.50% | ✗ | $4.9K |
| Sep 12, 2013 | Sep 12, 2013 | Tempest Therapeutics, Inc. | Chief Scientific Officer | Buy | 91.3 | +1,000 | 100.00% | ✗ | $10.3K |